Outcomes of six-dose high-dose cytarabine (HiDAC-6) as a salvage regimen for patients with relapsed/refractory acute myeloid leukemia (RR-AML).

被引：1
|
作者：
Veltri, Lauren Westfall [1 ]
Anders, Brandi [1 ]
Kanate, Abraham Sebastian [1 ]
Shillingburg, Alexandra [1 ]
Craig, Michael D. [1 ]
Cumpston, Aaron [1 ]
机构：
[1] West Virginia Univ, Morgantown, WV USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e18508
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18508
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study
    van Eijkelenburg, Natasha K. A.
    Rasche, Mareike
    Ghazaly, Essam
    Dworzak, Michael N.
    Klingebiel, Thomas
    Rossig, Claudia
    Leverger, Guy
    Stary, Jan
    De Bont, Eveline S. J. M.
    Chitu, Dana A.
    Bertrand, Yves
    Brethon, Benoit
    Strahm, Brigitte
    van der Sluis, Inge M.
    Kaspers, Gertjan J. L.
    Reinhardt, Dirk
    Zwaan, C. Michel
    HAEMATOLOGICA, 2018, 103 (09) : 1484 - 1492
  • [42] Effective salvage therapy for high-risk relapsed or refractory acute myeloid leukaemia with cisplatin in combination with high-dose cytarabine and etoposide
    Lee, Yun-Gyoo
    Kwon, Ji-hyun
    Kim, Inho
    Yoon, Sung Soo
    Lee, Jong-Seok
    Park, Seongyang
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2014, 92 (06) : 478 - 484
  • [43] Randomized phase II trial of the nucleolin targeting aptamer AS1411 combined with high-dose cytarabine in relapsed/refractory acute myeloid leukemia (AML)
    Stuart, R. K.
    Stockerl-Goldstein, K.
    Cooper, M.
    Devetten, M.
    Herzig, R.
    Medeiros, B.
    Schiller, G.
    Wei, A.
    Acton, G.
    Rizzieri, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [44] The Use of Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML): Clinical Outcomes and Their Predictors in a Large International Patient Cohort
    Stahl, Maximilian
    Podoltsev, Nikolai A.
    DeVeaux, Michelle
    Perreault, Sarah
    Itzykson, Raphael
    Ritchie, Ellen K.
    Sekeres, Mikkael A.
    Fathi, Amir T.
    Komrokji, Rami S.
    Bhatt, Vijaya R.
    Al-Kali, Aref
    Cluzeau, Thomas
    Santini, Valeria
    Brunner, Andrew
    Roboz, Gail J.
    Fenaux, Pierre
    Litzow, Mark
    Vey, Norbert
    Verma, Vivek
    Germing, Ulrich
    Fernandez, Pau Montesinos
    Zelterman, Daniel
    Kim, Tae Kon
    Prebet, Thomas
    Gore, Steven D.
    Zeidan, Amer M.
    BLOOD, 2016, 128 (22)
  • [45] Allogenic stem cell transplant (ASCT) as initial salvage for patients (pts) with acute myeloid leukemia (AML) refractory to high-dose cytarabine-based induction chemotherapy
    Daver, Naval Guastad
    De Lima, Marcos J. G.
    Kantarjian, Hagop
    Ravandi, Farhad
    Bilen, Mehmet Asim
    Pierce, Sherry
    Khouri, Issa F.
    Dorkhom, Stephan Joseph
    Giralt, Sergio
    Garcia-Manero, Guillermo
    Nazha, Aziz
    Mathisen, Michael
    Pemmaraju, Naveen
    Cortes, Jorge E.
    Faderl, Stefan
    Jabbour, Elias
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [46] Sense and nonsense of high-dose cytarabine for acute myeloid leukemia
    Lowenberg, Bob
    BLOOD, 2013, 121 (01) : 26 - 28
  • [47] ALLOGENIC STEM CELL TRANSPLANT (ASCT) AS INITIAL SALVAGE FOR PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) REFRACTORY TO HIGH-DOSE CYTARABINE-BASED INDUCTION CHEMOTHERAPY
    Cornelison, M.
    Daver, N.
    De Lima, M.
    Kantarjian, H.
    Ravandi, F.
    Pierce, S.
    Khouri, I.
    Giralt, S.
    Oran, B.
    Garcia-Manero, G.
    Jabbour, E.
    HAEMATOLOGICA, 2012, 97 : 34 - 34
  • [48] Acute Hepatotoxicity After High-Dose Cytarabine for the Treatment of Relapsed Acute Myeloid Leukemia: A Case Report
    Fu, Samuel H.
    Flannery, Alexander H.
    Bastin, Melissa L. Thompson
    HOSPITAL PHARMACY, 2019, 54 (03) : 160 - 164
  • [49] High-Dose Cytarabine (HiDAC) Improves the Cure Rate of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): Is It Better to be Given As Induction Therapy or As Consolidation Therapy?
    Schwarer, Anthony P.
    Wight, Joel
    Jackson, Kathryn
    Beligaswatte, Ashanka Mahilal
    Butler, Jason P.
    Kennedy, Glen
    Martin, Louisa
    Lewis, Ian D.
    Hiwase, Devendra
    Zantomio, Daniela
    He, Simon Z.
    Grigg, Andrew
    Morris, Kirk
    Mollee, Peter
    Marlton, Paula
    BLOOD, 2016, 128 (22)
  • [50] A phase I trial of liposomal daunorubicin (Daunoxome®) administered with high-dose cytarabine (HiDAC) to patients (pts) with relapsed acute leukemia (AL).
    Cripe, L
    Kneebone, P
    Roberts, L
    Mukwaya, G
    Rutledge, C
    Gordon, M
    BLOOD, 1998, 92 (10) : 233A - 233A
12345